Eur Rev Med Pharmacol Sci 2020; 24 (1): 267-273

DOI: 10.26355/eurrev_202001_19921

MiR-5195-3p inhibits the proliferation of glioma cells by targeting BIRC2

J. Yang, D.-M. Yan, L.-X. Xhu, D.-M. Si, Q.-H. Liang

Department of Neurosurgery, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, China. liangqinghua251@126.com


OBJECTIVE: The aim of this study was to investigate the effects of microRNA-5195-3p (miR-5195-3p) on the proliferation of glioma cells and to explore its related mechanisms.

PATIENTS AND METHODS: The expression level of miR-5195-3p in glioma tissues and cell lines was detected by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). Online prediction websites (TargetScan and miRanda) were used to screen the potential targets of miR-5195-3p. Luciferase reporter gene assay and Western blot were performed to confirm the targets of miR-5195-3p. Furthermore, the effects of miR-5195-3p on cell proliferation were detected by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide), colony formation assay, and flow cytometry, respectively.

RESULTS: MiR-5195-3p was lowly expressed in both glioma tissues and cells. Baculoviral IAP repeat-containing 2 (BIRC2) was identified as a direct target of miR-5195-3p. Over-expression of miR-5195-3p in glioma cells significantly decreased the protein expression of BIRC2. Besides, the proliferative capacity and colony formation ability were significantly inhibited after transfection of miR-5195-3p in vitro. In addition, flow cytometry indicated that an evident G1 phase arrest occurred in miR-5195-3p over-expressed group.

CONCLUSIONS: In this work, we emphasized the suppressor function of miR-5195-3p in the proliferation of glioma cells. Furthermore, our findings provided an experimental basis for the research and treatment of glioma.

Free PDF Download

To cite this article

J. Yang, D.-M. Yan, L.-X. Xhu, D.-M. Si, Q.-H. Liang
MiR-5195-3p inhibits the proliferation of glioma cells by targeting BIRC2

Eur Rev Med Pharmacol Sci
Year: 2020
Vol. 24 - N. 1
Pages: 267-273
DOI: 10.26355/eurrev_202001_19921